Realizing the promise of decentralized clinical trials

28 September 2020

An Expert View from Karen Noonan at the Association of Clinical Research Organizations (ACRO) on adopting a more flexible approach to trials moving forward, something made all the more important by the COVID-19 pandemic.

Picture this: you are a patient participating in a highly complex clinical trial that has the potential to not only help generate data about treatment for a difficult-to-manage condition, but also create meaningful change for patients like you.

This exciting, albeit time-consuming, experience becomes part of your routine life, with regular travel to the clinical trial site.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK